

Actual Revenue
\$11bn

Target Revenue
\$8bn

Actual Quantity


27M

Target Quantity
21M


Total Products


240

Total Transaction
214K




















PRODUCT PERFORMANCE

ProductClass	Sales Share	Actual Revenue	Target Revenue	Actual Revenue YTD	Target Revenue YTD	Actual Revenue PYTD	Target Revenue PYTD	Actual Revenue SPLY	Target Revenue SPLY
Antimalarial	12.6%	\$1,404,661,343	\$874,664,964	\$365,787,131	\$250,975,632	\$395,261,352	\$228,070,548	\$1,038,874,212	\$623,689,332
Antibiotics	14.9%	\$1,652,047,455	\$1,236,828,504	\$409,547,262	\$354,962,376	\$427,287,886	\$322,535,136	\$1,242,500,193	\$881,866,128
Antipiretics	16.0%	\$1,773,574,965	\$1,357,559,820	\$415,940,114	\$389,548,944	\$450,177,715	\$353,991,276	\$1,357,634,851	\$968,010,876
Mood Stabilizers	17.4%	\$1,937,812,289	\$1,582,942,152	\$463,782,173	\$454,170,120	\$470,527,569	\$412,733,928	\$1,474,030,116	\$1,128,772,032
Antiseptics	18.9%	\$2,103,318,224	\$1,675,284,228	\$513,537,361	\$480,688,116	\$543,441,889	\$436,803,996	\$1,589,780,863	\$1,194,596,112
Analgesics	20.2%	\$2,246,694,793	\$1,726,046,856	\$491,078,374	\$495,237,588	\$644,241,692	\$450,082,212	\$1,755,616,419	\$1,230,809,268
Total	100.0%	\$11,118,109,069	\$8,453,326,524	\$2,659,672,415	\$2,425,582,776	\$2,930,938,103	\$2,204,217,096	\$8,458,436,654	\$6,027,743,748



Actual Revenue
\$11bn

Target Revenue

\$8bn

Actual Quantity

27M

Target Quantity

21M


Total Products


240

Total Transaction
214K

✓ □ 2022✓ □ 2023✓ □ 2024✓ □ 2025







ProductClass	Actual Revenue	Total Quantity Sold		
Analgesics	\$2,246,694,793	5,259,892		
Antiseptics	\$2,103,318,224	5,170,828		
Mood Stabilizers	\$1,937,812,289	4,870,408		
Antipiretics	\$1,773,574,965	3,816,478		
Antibiotics	\$1,652,047,455	3,902,861		
Antimalarial	\$1,404,661,343	3,983,982		

Product Class
Analgesics
Antibiotics
Antimalarial
Antipiretics
Antiseptics
☐ Mood Stabilizers

SALES REPRESENTATIVE PERFORMANCE

Name	Actual Revenue	Target Revenue	Actual Quantities	Target Quantities	TargetRevenue Achieved %
Abigail Thompson	\$929,427,257	\$712,012,896	2,179,360	1,772,592	8.42%
Jimmy Grey	\$928,946,974	\$582,276,732	2,153,474	1,463,316	6.89%
Sheila Stones	\$903,565,506	\$638,908,128	2,252,562	1,529,244	7.56%
Daniel Gates	\$895,102,799	\$588,161,220	2,180,288	1,522,572	6.96%
Anne Wu	\$864,742,861	\$776,594,688	2,100,608	1,799,076	9.19%
Morris Garcia	\$844,681,990	\$702,790,524	2,119,503	1,720,944	8.31%
Stella Given	\$840,996,176	\$505,221,504	1,991,933	1,325,064	5.98%
Jessica Smith	\$832,986,693	\$715,518,168	2,019,806	1,769,328	8.46%
Mary Gerrard	\$827,667,061	\$700,871,196	1,984,219	1,587,852	8.29%
Steve Pepple	\$826,877,475	\$594,339,972	2,119,077	1,430,580	7.03%
Erica Jones	\$820,502,748	\$615,910,728	2,010,356	1,523,196	7.29%
Thompson Crawford	\$811,335,850	\$645,217,872	1,965,181	1,501,584	7.63%
Alan Ray	\$791,275,679	\$675,502,896	1,928,082	1,559,796	7.99%
Total	\$11,118,109,069	\$8,453,326,524	27,004,449	20,505,144	100.00%

